The twin drug approach for novel nicotinic acetylcholine receptor ligands

Add time:08/18/2019    Source:sciencedirect.com

The association of two pharmacophoric entities generates so-called ‘twin drugs’ or dimer derivatives. We applied this approach for the design of a small compound library for the interaction with α4β2∗ nicotinic acetylcholine receptors (nAChRs). In this compound series, the nAChR ligand N,N-dimethyl-2-(pyridin-3-yloxy)ethan-1-amine 9 served as one pharmacological entity and it was initially kept constant as one part of the ‘twin’ compound. ‘Twin’ compounds with identical or non-identical entities using the ‘no linker mode’ or ‘overlap’ mode were synthesized and evaluated for their nAChR affinities. Compound 17a showed the highest affinity for the α4β2∗ nAChR subtype (Ki = 0.188 nM) and its (di)fluoro analogs could retain nanomolar affinities, when replacing pyridine as the hydrogen bond acceptor system by mono- or difluoro-phenyls. The ‘twin drug’ approach proved to provide compounds with high affinity and subtype selectivity for α4β2∗ nAChRs.

We also recommend Trading Suppliers and Manufacturers of 6-(4-Methylpiperazin-1-yl)nicotinic acid (cas 132521-70-1). Pls Click Website Link as below: cas 132521-70-1 suppliers

Prev:Research paperBis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats
Next:New ACE-inhibitory peptides derived from α-lactalbumin produced by hydrolysis with Bromelia antiacantha peptidases)